One lasts longer. The other hits harder. Both carry growth-factor risks that most forums won’t tell you about.

Related Guides

Quick Facts

Different engineering decisions, different pharmacokinetic profiles—and no clinical trial evidence for either in the context people use them

—

EDUCATIONAL NOTICE This article is for educational purposes and does not constitute medical advice. Neither IGF-1 LR3 nor IGF-1 DES is approved by the FDA for performance enhancement, muscle growth, or use in healthy adults. Both compounds are prohibited by WADA (S2—peptide hormones, growth factors) and are Schedule III controlled substances in some jurisdictions. The peptide research community operates in a legal and regulatory gray zone. Using these compounds carries real medical risks, including hypoglycemia, acromegalic changes, and potential cancer promotion. This article exists to explain the compounds accurately, not to encourage their use.

↑ Back to top

Quick Summary (11th Grade)

Your body naturally produces insulin-like growth factor 1 (IGF-1) in the liver. It’s one of the main signals that tells your muscles, bones, and organs to grow. When you inject growth hormone, your liver cranks out more IGF-1—that’s how GH actually does its work. Scientists have tweaked IGF-1 in the lab to make modified versions: one (LR3) stays in your bloodstream far longer, and another (DES) works more aggressively for shorter periods. Both versions activate the same growth machinery in your cells that make your muscles bigger. The problem is, that same machinery also makes other cells bigger—including cancer cells. The research establishment has never tested either modified version on healthy people trying to build muscle. The bodybuilding community has used them for decades based on self-experimentation and theory. This article separates what we actually know from what people assume, and explains what makes these two variants different.

↑ Back to top

Table of Contents

1. What They Are—The Parent Peptide and Its Modifications
2. How They Work—Same Receptor, Different Kinetics
3. The Modifications Explained—LR3 vs DES Engineering
4. The Evidence Problem—What We Know and What We Assume
5. Head-to-Head Comparison Table
6. The IGF-1 Receptor and Cell Proliferation—Cancer Risk Explained
7. Practical Differences for Community Use
8. Follistatin—The Alternate Approach (Brief)
9. Safety Beyond Cancer
10. Frequency Asked Questions
11. Summary
12. Selected References

↑ Back to top

1. What They Are—The Parent Peptide and Its Modifications

Native IGF-1: The Original

Insulin-like Growth Factor 1 (IGF-1) is a 70-amino-acid peptide hormone produced primarily by the liver, though many tissues synthesize local variants. It is one of the most important anabolic signals in vertebrate physiology—responsible for growth during childhood and adolescence, and for the maintenance of tissue integrity and repair throughout life.

The mechanism is straightforward: growth hormone (GH) tells the liver to produce more IGF-1, and IGF-1 does the actual work. GH without IGF-1 is mostly ineffective. IGF-1 without GH still works.

Native IGF-1 has a half-life of approximately 10–15 minutes in circulation. This brief lifespan is by design. The body tightly controls its growth signaling. This is achieved through a family of IGF binding proteins (IGFBPs)—primarily IGFBP-3 in serum—that sequester circulating IGF-1 and prevent it from freely diffusing into tissues. Only a tiny fraction of circulating IGF-1 is “free” and bioavailable at any given moment. The IGFBP system is the body’s way of rate-limiting growth signaling.

IGF-1 LR3: The Long Player

IGF-1 LR3 (Long-Arg3 IGF-1) is a recombinant analog engineered with two key modifications:

1. The Long: a 13-amino-acid N-terminal extension derived from human insulin-like growth factor II (IGF-II)
2. The R3: a substitution of glutamic acid at position 3 with arginine

These changes accomplish one thing: they prevent IGFBPs from binding to the molecule. IGFBPs cannot recognize the modified N-terminus, so IGF-1 LR3 escapes sequestration. It circulates freely—bioavailable everywhere it travels. The result is a dramatic extension of active half-life: 20–30 hours instead of 15 minutes. The area-under-the-curve (AUC) for tissue exposure increases dramatically.

IGF-1 LR3 was originally developed as a research tool for cell culture and animal studies. It is highly reproducible, long-acting, and well-characterized in the scientific literature. Thousands of papers study it in vitro and in rodents. It has never been tested clinically in humans for performance enhancement.

IGF-1 DES: The Potent Player

IGF-1 DES (des(1-3) IGF-1) is engineered differently. The modification is a deletion: the first three N-terminal amino acids are removed. This truncation also reduces IGFBP binding, but less dramatically than LR3’s approach. The half-life is moderately extended compared to native IGF-1—likely in the range of 4–6 hours, though precise characterization in humans is unavailable.

Where DES differs is in receptor occupancy. In cell-based assays, IGF-1 DES is approximately 10 times more potent than native IGF-1 at activating the IGF-1 receptor on a per-molecule basis. The truncated N-terminus positions the active core of the molecule more favorably for receptor binding.

IGF-1 DES was originally identified as a naturally occurring variant in the brain. It has also been studied extensively in research contexts—cell culture, rodents, primates—but has no clinical development history for performance applications.

↑ Back to top

2. How They Work—Same Receptor, Different Kinetics

The Shared Mechanism

Both IGF-1 LR3 and IGF-1 DES work through the exact same receptor: IGF-1R (insulin-like growth factor 1 receptor). This is a transmembrane tyrosine kinase. When IGF-1 or its analogs bind to IGF-1R, the receptor autophosphorylates and triggers downstream signaling cascades.

The two primary pathways are:

Both pathways can promote anabolism in muscle tissue. Both pathways also promote cell division and survival in other cell types—including tumor cells.

The pharmacodynamics (what the drug does at the receptor) are identical. The differences between LR3 and DES are purely pharmacokinetic.

Why the Kinetics Matter

IGF-1 LR3: Because IGFBP binding is nearly abolished, the compound achieves sustained, high circulating free IGF-1 levels. This creates a persistent—almost continuous—growth stimulus. A single injection of LR3 sustains elevated IGF-1 signaling for 20–30 hours. The effect is systemic: every tissue expressing IGF-1R experiences prolonged activation. Muscle grows. But so does cartilage. So do organ cells. So do any malignant cells present.

IGF-1 DES: The shorter half-life (4–6 hours estimated) and somewhat retained IGFBP binding mean lower circulating steady-state levels. Per-molecule potency is higher, but total bioavailability is lower than LR3 at comparable doses. Some community protocols attempt localized injection near target muscles, though the evidence for truly localized effect is weak—DES still enters systemic circulation rapidly.

↑ Back to top

3. The Modifications Explained—LR3 vs DES Engineering

LR3: Escaping IGFBP Binding

The 13-amino-acid N-terminal extension is derived from IGF-II. By adding this “foreign” sequence, the molecule becomes unrecognizable to IGFBP-3 and other major binding proteins. IGFBP binding is reduced by approximately 100-fold to 1000-fold compared to native IGF-1.

Consequence: LR3 acts as a systemic, long-acting growth factor. It is used in bodybuilding and performance communities at doses typically ranging from 20–100 micrograms per day, often as a once-daily subcutaneous or intramuscular injection.

The IGFBP-escape strategy is elegant for research purposes: it produces reproducible, sustained levels without the confounding variable of binding protein dynamics.

DES: Potency Over Duration

The des(1-3) truncation removes the N-terminus while preserving the core IGF-1 scaffold. This yields two consequences:

1. A moderate reduction in IGFBP binding (less dramatic than LR3)
2. A higher occupancy rate at the IGF-1 receptor itself

The net result is higher potency per mole but a shorter total duration. Some community protocols inject DES multiple times daily at lower doses—10–50 micrograms twice daily or more—to maintain more stable levels despite the shorter half-life.

A minority of users attempt localized injection directly into or near target muscles, based on the theory that local IGF-1 concentrations would exceed systemic ones. The degree to which this actually prevents systemic action is debated; blood flow from muscle is robust, and the molecule rapidly reaches systemic circulation.

↑ Back to top

4. The Evidence Problem—What We Know and What We Assume

The Tier 4 Reality

There are no randomized controlled trials in healthy humans comparing IGF-1 LR3 or IGF-1 DES to placebo for muscle growth, strength gain, or performance enhancement. None. Zero.

This is Tier 4 evidence—preclinical work only. Both compounds are well-characterized in cell culture and animal models. The pharmacology is understood. The mechanism is clear. But the clinical evidence for efficacy in the stated use case (performance enhancement in athletes or bodybuilders) simply does not exist.

What exists instead:

• Cell culture research: thousands of papers showing IGF-1, LR3, and DES promote myocyte protein synthesis and proliferation
• Animal models: extensive literature on rodent and primate muscle growth in response to IGF-1 analogs
• Bodybuilding community experience: decades of self-experimentation, anecdotal reports on forums, underground lab (UGL) protocols

The Community Experience Gap

The bodybuilding and performance enhancement community has used IGF-1 LR3 since the 1990s and DES since the early 2000s. There is a large body of collective experience. Users report muscle gains, improved recovery, and systemic anabolic effects. Forums contain thousands of protocol discussions, dosing strategies, and adverse event reports.

This is not clinical evidence. It is valuable observational data with multiple confounders:

• Concurrent use of anabolic steroids (which also drive muscle growth)
• Variation in diet, training stimulus, and genetics
• Lack of placebo control
• Lack of objective measurement (most reports are subjective assessment)
• Selection bias (those who had positive experiences are more likely to report)
• Survivorship bias (users who experienced severe adverse effects may not be posting)

The absence of reported severe adverse events on community forums does not equal safety data. It means those events either did not occur in that population, or were not reported, or the causality was not recognized.

What We Know With Certainty

1. Mechanism: Both LR3 and DES activate IGF-1R and downstream growth pathways—established biochemistry
2. Pharmacokinetics: LR3 half-life of 20–30 hours; DES shorter but uncharacterized precisely in humans
3. IGFBP binding: LR3 avoids it nearly completely; DES reduces it significantly
4. Research use: both are standard tools in cell and animal research
5. No human efficacy trials: neither compound has clinical trial data for performance enhancement

What We Assume But Cannot Confirm

1. That community-reported muscle gains are primarily due to these compounds (vs. other variables)
2. That the observed adverse events in community reports represent the actual incidence (vs. unrecognized or unreported events)
3. That dosing protocols developed in the community are safe (they are not based on human pharmacokinetics or safety data)
4. That localized injection of DES produces localized effects (evidence is weak)

↑ Back to top

5. Head-to-Head Comparison Table

↑ Back to top

6. The IGF-1 Receptor and Cell Proliferation—Cancer Risk Explained

The Mechanism Cannot Be Separated From the Effect

This is the core issue that makes these compounds “thin ice.” The same biological mechanism that makes them anabolic in muscle—activation of IGF-1R and downstream Akt/mTOR/ERK signaling—promotes cell proliferation and survival in all cell types that express IGF-1R. This is not a side effect. This is the mechanism.

You cannot have muscle growth signaling without cell proliferation signaling. They are the same pathway.

Epidemiological Evidence: IGF-1 and Cancer Risk

Prospective cohort studies and meta-analyses consistently show associations between elevated circulating IGF-1 levels and increased cancer risk:

• Colorectal cancer: elevated IGF-1 is associated with 1.5–2.5x increased risk
• Breast cancer: elevated IGF-1 is associated with ~1.3–1.7x increased risk (stronger in premenopausal women)
• Prostate cancer: elevated IGF-1 is associated with ~1.5–2.0x increased risk
• Lung cancer: elevated IGF-1 is associated with increased risk (effect size varies by study)

These are population-level associations. They do not prove causation in any individual. But they are consistent across decades of research and multiple study designs. The biological plausibility is high: IGF-1R is expressed on epithelial cells throughout the body, and IGF-1R signaling promotes survival and proliferation.

Why This Matters for LR3 vs DES

IGF-1 LR3 sustains circulating free IGF-1 levels for 20–30 hours. A single injection of LR3 creates prolonged, sustained IGF-1R activation throughout the body. Over weeks and months of use, users essentially maintain a state of chronic, supraphysiological IGF-1 signaling.

IGF-1 DES, due to its shorter half-life, creates episodic elevation—high peaks, lower troughs. The total area-under-the-curve (cumulative exposure) is lower than LR3 at comparable molar doses.

From a cancer promotion perspective, LR3’s sustained signaling profile represents a theoretically greater risk than DES’s pulsatile profile. But both are activating the pro-proliferation pathway.

The Unknowable Part

We do not know the absolute cancer risk increment from using these compounds in young, healthy people. The epidemiological data apply to population-level circulating IGF-1 elevations, not to the pharmacological doses and durations used in bodybuilding. We have no long-term follow-up studies of people who have used IGF-1 LR3 or DES. The compounds have been in the bodybuilding community for 20–25 years, so long-term cancer outcomes would be starting to appear in users from the 1990s, but there is no centralized registry tracking this.

↑ Back to top

7. Practical Differences for Community Use

IGF-1 LR3 in Practice

Typical protocol: 20–100 micrograms per day, often administered as a single daily subcutaneous or intramuscular injection. Some users prefer splitting the dose.

Rationale: the long half-life allows once-daily dosing, simplifying compliance.

Reported effects: sustained anabolism, improved appetite, improved recovery, systemic muscle growth.

User base: common in bodybuilding and strength sports, often stacked with other compounds in complex protocols.

IGF-1 DES in Practice

Typical protocol: 10–50 micrograms per injection, 2–3 times daily, either systemically or (less commonly) via localized injection.

Rationale: the shorter half-life requires more frequent dosing to maintain steady levels. Higher per-molecule potency allows lower absolute doses.

Reported effects: potent anabolism, potentially more localized effect if injected near target muscle (though this is debated), faster onset and offset compared to LR3.

User base: smaller community than LR3, often favored by those seeking higher potency or shorter duration.

Neither Has Clinical Dosing Guidance

All community dosing is empirical, based on self-experimentation and forum discussion. Neither compound has been studied in humans for performance enhancement, so we have no data on optimal dose, frequency, duration, or safety margins. The protocols in use are best described as “educated guesses based on mechanism and anecdotal feedback.”

↑ Back to top

8. Follistatin—The Alternate Approach (Brief)

Cluster N includes follistatin, which represents an entirely different pharmacological strategy. Rather than adding more growth signal (as IGF-1 LR3 and DES do), follistatin blocks myostatin—an inhibitor of muscle growth. The mechanism is fundamentally different: myostatin knockout produces massive muscle hypertrophy in animals.

Follistatin is not a direct comparator to the IGF-1 variants, but it represents the alternative approach in the peptide performance community: removing the brakes on growth, rather than pressing harder on the accelerator.

↑ Back to top

9. Safety Beyond Cancer

Hypoglycemia: Immediate and Real

Both IGF-1 LR3 and IGF-1 DES have potent insulin-like metabolic effects. They stimulate glucose uptake in muscle and fat tissue. They suppress hepatic glucose output. The net result is a real risk of hypoglycemia—dangerously low blood sugar.

This is not theoretical. Community reports of hypoglycemic episodes are common—confusion, shakiness, sweating, rapid heart rate, sometimes loss of consciousness. Hypoglycemia is an immediate medical emergency; severe, prolonged hypoglycemia causes seizures and death.

Users mitigate this through careful food timing (eating carbohydrates around injection times) and monitoring, but the risk remains. A user on vacation with disrupted meal timing, or someone who miscalculates, is at real risk.

Acromegalic Changes: Chronic Soft-Tissue Overgrowth

Chronic supraphysiological IGF-1 (as occurs in acromegaly or with exogenous IGF-1 use) produces characteristic soft-tissue growth:

• Joint cartilage thickening (leading to joint pain and dysfunction)
• Organ enlargement (cardiomegaly, hepatomegaly, splenomegaly)
• Bone density changes and increased fracture risk
• Facial feature changes (jaw growth, hand/foot enlargement)
• Skin thickening and coarsening

Long-term users report these changes—thickened knuckles, enlarged hands, jaw changes. Some are reversible upon cessation; some are permanent.

Fluid Retention and Cardiovascular Stress

IGF-1 is anabolic to cardiac muscle. It can also cause sodium retention and fluid accumulation. Users report bloating, water retention, and increased blood pressure. Combined with concurrent use of other compounds (anabolic steroids, growth hormone), the cardiovascular load can be significant.

Interaction With Other Peptides and Hormones

Many users combine IGF-1 LR3 or DES with growth hormone secretagogues (CJC-1295 (no DAC), GHRP-2, GHRP-6), exogenous growth hormone, and anabolic steroids. These combinations create compounding IGF-1 elevation:

• GH secretagogues → more endogenous GH → more endogenous IGF-1
• Exogenous IGF-1 analogs → direct IGF-1R activation
• Anabolic steroids → increased GH secretion and IGF-1 expression
• The combined effect is an additive or synergistic elevation of growth signaling

The safety profile of these combinations is entirely unexplored. We have no data on interaction effects, cumulative toxicity, or long-term outcomes.

↑ Back to top

10. Frequently Asked Questions

11. Summary

IGF-1 LR3 and IGF-1 DES are recombinant analogs of endogenous insulin-like growth factor 1, engineered to evade the body’s natural binding protein system and extend bioavailability. They are potent activators of growth signaling in all tissues that express the IGF-1 receptor—including muscle, bone, organs, and cancer cells.

IGF-1 LR3 is the longer-acting version, engineered with an N-terminal extension and arginine substitution that nearly eliminates IGFBP binding. Half-life extends from ~15 minutes to 20–30 hours. Community use typically involves once-daily injection at 20–100 micrograms.

IGF-1 DES is the more potent version on a per-molecule basis, engineered by deletion of the first three N-terminal amino acids. Half-life is shorter (~4–6 hours estimated). Community use typically involves multiple daily injections at 10–50 micrograms.

Both are Tier 4 evidence for performance enhancement—preclinical research only, with no clinical trial data in healthy humans. Decades of bodybuilding community experience provide observational data, but this is confounded by concurrent use of other compounds, lack of objective measurement, and lack of placebo control.

The major safety concern—one that cannot be separated from the mechanism of action—is cancer promotion. IGF-1 signaling is linked to increased risk of colorectal, breast, prostate, and lung cancers in epidemiological studies. LR3’s sustained systemic signaling profile represents higher theoretical cancer risk than DES’s shorter duration, but both activate the pro-proliferation pathway.

Additional safety concerns include immediate hypoglycemia risk (managed through careful nutrition but real), chronic acromegalic changes (partially reversible), and interactions with other performance compounds.

Neither IGF-1 LR3 nor IGF-1 DES is approved by any regulatory authority for performance enhancement. Both are WADA prohibited (S2—peptide hormones, growth factors). Both are used in the bodybuilding community based on mechanism, animal data, and collective experience.

The honest assessment: both work (in the context of hypertrophy programming and concurrent training stimulus), both carry real medical risks, and neither has clinical evidence supporting their safety or efficacy in the intended use. The decision to use these compounds is a risk-benefit calculation that each individual must make with full awareness of the risks.

↑ Back to top

12. Selected References

IGF-1 Receptor Signaling and Mechanism

1. Siddle, K. (2011). Signalling by insulin and IGF receptors: supporting acts and new players. Journal of Molecular Endocrinology, 47(1), R1–R10.
2. Clemmons, D. R. (2004). The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. The Journal of Clinical Investigation, 113(1), 25–27.

IGF-1 LR3 and DES Characterization

1. Zapf, J., Kiefer, M., Merryweather, R., et al. (1990). Isolation and characterization of a cDNA clone encoding a novel variant of insulin-like growth factor 1 with a long N-terminal extension. Journal of Biological Chemistry, 265(24), 14892–14898.
2. Guler, H. P., Schmid, C., Zapf, J., & Froesch, E. R. (1989). Effects of recombinant insulin-like growth factor I on insulin secretion and renal sodiumexcretion in humans. Proceedings of the National Academy of Sciences, 86(9), 2868–2872.
3. Osako, M., Yonezawa, T., & Inui, A. (1996). Des(1-3)IGF-I and insulin-like growth factor-I analogues: effects on differentiation of mouse myoblasts. Journal of Endocrinology, 149(2), 273–281.

IGF-1 and Cancer Risk (Epidemiology)

1. Renehan, A. G., Zwahlen, M., Minder, C., O’Dwyer, S. T., Shalet, S. M., & Egger, M. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-analysis. The Lancet, 363(9418), 1346–1353.
2. Shimokata, H., Murayama, N., Kuzuya, F., et al. (1993). Correlation of circulating immunoreactive insulin-like growth factor-I and its binding protein-3 with age in healthy subjects. Journal of Clinical Endocrinology & Metabolism, 71(6), 1642–1649.
3. Holmes, M. D., Pollak, M. N., Morris, J. S., et al. (2002). Insulin-like growth factor-I and risk of breast cancer: a prospective study. Journal of the National Cancer Institute, 94(18), 1362–1368.
4. Chan, J. M., Stampfer, M. J., Giovannucci, E., et al. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279(5350), 563–566.

IGFBP Binding and Pharmacokinetics

1. Baxter, R. C. (2000). Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. American Journal of Physiology—Endocrinology and Metabolism, 278(6), E967–E976.

Acromegaly and IGF-1 Side Effects

1. Chanson, P., & Salenave, S. (2008). Metabolic abnormalities in acromegaly. Nature Reviews Endocrinology, 4(7), 407–413.
2. Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004). Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews, 25(1), 102–152.

Growth Hormone Secretagogues and IGF-1 Interaction

1. Bowers, C. Y. (2010). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 46(5), 389–394.

—

PMID verification note: Full PMID citations should be verified against PubMed database before final publication. Article citations above are structured for Chicago Manual of Style (16th ed.).

—

Status: Ready for editorial review, fact-checking verification on cancer epidemiology citations, and PMID confirmation.

↑ Back to top

---